Application of a three-dimensional graft of autologous osteodifferentiated adipose stem cells in patients undergoing minimally invasive transforaminal lumbar interbody fusion: clinical proof of concept

Fomekong, Edward; Dufrane, Denis; Berg, BC Vande; André, Wivine; Aouassar, Najima; Vériter, Sophie; Raftopoulos, Christian

doi:10.1007/s00701-016-3051-6

Cited by 14 publications

(9 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies that explored the potential of MSCs for spinal fusion have demonstrated that the use of MSCs produced outcomes comparable to those of iliac crest grafts in terms of histology and mechanical properties [ 209 , 210 ]. Regarding clinical trials involving application of ADSCs to degenerative spondylolisthesis, one study covered by this review reported that the use of 3D graft made of autologous ADSCs in patients receiving minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) resulted in significant improvement in the VAS score and the ODI and achievement of grade 3 fusion without donor site complications [ 196 ]. Although only one study did not guarantee the clinical benefit of using ADSCs for degenerative spondylolisthesis so that further studies are required, a very recent study where a combination of BM-MSC and allogeneic graft achieved a higher rate of posterior spinal fusion and radiographic complete response without significant AEs [ 211 ] also suggests the potential of ADSCs, or stem cells in general, as alternative therapeutics for degenerative spondylolisthesis.…”

Section: Type Of Msds Targetedmentioning

confidence: 99%

ADSC-Based Cell Therapies for Musculoskeletal Disorders: A Review of Recent Clinical Trials

Lee

Chae

Song

et al. 2021

IJMS

View full text Add to dashboard Cite

Recently published clinical trials involving the use of adipose-derived stem cells (ADSCs) indicated that approximately one-third of the studies were conducted on musculoskeletal disorders (MSD). MSD refers to a wide range of degenerative conditions of joints, bones, and muscles, and these conditions are the most common causes of chronic disability worldwide, being a major burden to the society. Conventional treatment modalities for MSD are not sufficient to correct the underlying structural abnormalities. Hence, ADSC-based cell therapies are being tested as a form of alternative, yet more effective, therapies in the management of MSDs. Therefore, in this review, MSDs subjected to the ADSC-based therapy were further categorized as arthritis, craniomaxillofacial defects, tendon/ligament related disorders, and spine disorders, and their brief characterization as well as the corresponding conventional therapeutic approaches with possible mechanisms with which ADSCs produce regenerative effects in disease-specific microenvironments were discussed to provide an overview of under which circumstances and on what bases the ADSC-based cell therapy was implemented. Providing an overview of the current status of ADSC-based cell therapy on MSDs can help to develop better and optimized strategies of ADSC-based therapeutics for MSDs as well as help to find novel clinical applications of ADSCs in the near future.

show abstract

Section: Type Of Msds Targetedmentioning

confidence: 99%

ADSC-Based Cell Therapies for Musculoskeletal Disorders: A Review of Recent Clinical Trials

Lee

Chae

Song

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…They reported on no complications and observed an improvement in pain and disability scores. Two of three evaluated segments showed bony fusion in the CT scans [56].…”

Section: Studies Using Mscsmentioning

confidence: 91%

Mesenchymal stromal cell and bone marrow concentrate therapies for musculoskeletal indications: a concise review of current literature

et al. 2020

View full text Add to dashboard Cite

The interest on applying mesenchymal stromal cells (MSCs) in orthopedic disorders has risen tremendously in the last years due to scientific successes in preclinical in vitro and animal model studies. In a wide range of diseases and injuries of the musculoskeletal system, MSCs are currently under evaluation, but so far have found access to clinical use only in few cases. The current assignment is to translate the acquired knowledge into clinical practice. Therefore, this review aims at presenting a synopsis of the up-to-date status of the use of MSCs and MSC related cell products in musculoskeletal indications. Clinical studies were included, whereas preclinical and animal study data not have been considered. Most studies published so far investigate the final outcome applying bone marrow derived MSCs. In fewer trials the use of adipose tissue derived MSCs and allogenic MSCs was investigated in different applications. Although the reported results are equivocal in the current literature, the vast majority of the studies shows a benefit of MSC based therapies depending on the cell sources and the indication in clinical use. In summary, the clinical use of MSCs in patients in orthopedic indications has been found to be safe. Standardized protocols and clear definitions of the mechanisms of action and the mode and timing of application as well as further coordinated research efforts will be necessary for finally adding MSC based therapies in standard operating procedures and guidelines for the clinicians treating orthopedic disorders.

show abstract

“…Adipose-derived MSCs (rASCs) were isolated from the subcutaneous and inguinal fat pads of donor Lewis rats via enzymatic digestion as previously described. 23 Bone marrow MSCs (rBMCs) were obtained from the same Lewis rats via marrow flushing of the long bones as previously described. 33 These rASCs or rBMCs were cultured until passage 2 (P2) in basal culture media (Dulbecco's modified Eagle's medium (DMEM; high glucose; Gibco) supplemented with 10% fetal calf serum (FCS) and 1% (v:v) penicillin-streptomycin) at 37°C in humidified air with 5% CO 2 .…”

Section: Cell Isolation and Culturementioning

confidence: 99%

“…More importantly, studies have suggested that ASCs are less influenced by aging and skeletal conditions than marrow-derived progenitors. [17][18][19] However, the use of ASCs in spinal fusion procedures is only beginning to be explored, [20][21][22][23][24][25][26][27][28][29][30][31][32] with limited research directly comparing their performance to BMCs. 21,30 In this study, we thus directly compare the efficacy of ASCs and BMCs in achieving successful spinal fusion when combined with a clinical-grade bone graft substitute in a rat model.…”

mentioning

confidence: 99%

Comparing the efficacy of adipose‐derived and bone marrow‐derived cells in a rat model of posterolateral lumbar fusion

Holmes

Ishida

Perdomo‐Pantoja

et al. 2021

Journal Orthopaedic Research

View full text Add to dashboard Cite

Although bone marrow-derived mesenchymal stem cells (BMCs) have been widely used in spinal fusion procedures, adipose-derived stem cells (ASCs) offer a number of advantages as an alternative clinical cell source. This study directly compares the efficacy of ASCs and BMCs from the same donor animals to achieve successful fusion when combined with a clinical-grade bone graft substitute in a rat lumbar fusion model. ASCs and BMCs were isolated from the same Lewis donor rats and grown to passage 2 (P2).Single-level bilateral posterolateral intertransverse process lumbar fusion surgery was performed on syngeneic rats divided into three experimental groups: clinical-grade bone graft substitute alone (CBGS); CBGS+ rat ASCs (rASC); and, CBGS+ rat BMCs (rBMC).Eight weeks postoperatively, fusion was evaluated via micro-CT, manual palpation and histology. In vitro analysis of the osteogenic capacity of rBMCs and rASCs was also performed. Results indicated that the average fusion volume in the rASC group was the largest and was significantly larger than the CBGS group. Although the rASC group displayed the highest fusion rates via micro-CT and manual palpation, this difference was not statistically significant. Cell-seeded grafts showed more histological bone formation than cell-free grafts. P2 rASCs and rBMCs displayed similar in vitro osteogenic differentiation capacities. Overall, this study showed that, when combined with a clinical-grade bone graft substitute in a rat model, rASCs cells yielded the largest fusion masses and comparable fusion results to rBMCs. These results add to growing evidence that ASCs provide an attractive alternative to BMCs for spinal fusion procedures.adipose stem cell, animal model, bone marrow cell, mesenchymal stem cell, spine fusion | INTRODUCTIONSpinal fusion is an increasingly common procedure used to treat a variety of conditions arising from trauma, degenerative diseases, deformity, infection, and tumors. While generally successful, the current "gold standard" of care, which involves the use of autograft bone, still fails in up to 35% of cases, resulting in significant patient morbidity, the need for additional procedures, and increased health care costs. 1 A wide variety of clinical bone graft substitutes, extension systems and orthobiologics have thus been developed to

show abstract

Application of a three-dimensional graft of autologous osteodifferentiated adipose stem cells in patients undergoing minimally invasive transforaminal lumbar interbody fusion: clinical proof of concept

Abstract: A scaffold-free 3D graft made of AMSCs can be manufactured and used as a promising alternative for spinal fusion procedures. Nevertheless, further studies of a larger series of patients are needed to confirm its effectiveness.

Cited by 14 publications

References 50 publications

ADSC-Based Cell Therapies for Musculoskeletal Disorders: A Review of Recent Clinical Trials

ADSC-Based Cell Therapies for Musculoskeletal Disorders: A Review of Recent Clinical Trials

Mesenchymal stromal cell and bone marrow concentrate therapies for musculoskeletal indications: a concise review of current literature

Comparing the efficacy of adipose‐derived and bone marrow‐derived cells in a rat model of posterolateral lumbar fusion

Contact Info

Product

Resources

About